Glucagon-like peptide 1 (GLP-1) is an important incretin hormone secreted by L-cells of intestine that plays an important role in glucose and bodyweight homeostasis. The concept of incretin based therapies appeared on the horizon of diabetes management only over last two decades, especially after the approval of exenatide by Food and Drug Administration (FDA) in 2004. GLP-1-based therapies can be broadly classified into two categories—GLP-1 receptor agonists (GLP-1RA) and DPP-4 inhibitors (DPP-4i). This chapter covers the glucagon-like peptide 1 actions, comparison of the glucagon like peptide 1 receptor agonists, and choosing the appropriate glucagon-like peptide 1 receptor agonist. The GLP-1RA class improves glycemic control through multiple mechanisms with a low risk of hypoglycemia and facilitates clinically relevant weight loss.